Papillary thyroid carcinomas are characterized by rearrangements of the RET receptor tyrosine kinase generating RET/PTC oncogenes. Here we show that osteopontin (OPN), a secreted glycoprotein, is a major RET/PTC-induced transcriptional target in PC Cl 3 thyroid follicular cells. OPN upregulation depended on the integrity of the RET/PTC kinase and tyrosines Y1015 and Y1062, two major RET/PTC autophosphorylation sites. RET/PTC also induced a strong overexpression of CD44, a cell surface signalling receptor for OPN. Upregulation of CD44 was dependent on RET/PTC Y1062, as well. Constitutive OPN overexpression or treatment with exogenous recombinant OPN sharply increased proliferation, Matrigel invasion and spreading in collagen gels of RET/PTC-transformed PC Cl 3 cells. These effects were impaired by the treatment of PC Cl 3-RET/PTC cells with OPN-and CD44-blocking antibodies. Thus, RET/PTC signalling triggers an autocrine loop involving OPN and CD44 that sustains proliferation and invasion of transfomed PC Cl 3 thyrocytes.
Introduction
Papillary thyroid carcinoma (PTC) is the most prevalent malignancy of the thyroid gland. PTC hallmarks are chromosomal inversions or translocations that cause the recombination of the intracellular kinase-encoding domain of the RET receptor with heterologous genes, generating the RET/PTC chimeric oncogenes. RET/ PTC1, the H4-RET fusion, and RET/PTC3, the RFG-RET fusion, are the most prevalent variants (Fagin, 2002) . RET/PTC-transgenic mice develop PTC, proving that RET/PTC oncogenes are able to initiate thyroid carcinogenesis (Santoro et al., 1996; Buckwalter et al., 2002) .
Fusion with protein partners possessing proteinprotein interaction motifs provides RET/PTC kinases with dimerizing interfaces. This results in constitutive dimerization and phosphorylation of the chimeric oncoproteins and constant upregulation of signal transduction. RET signalling mainly depends on three key tyrosine residues: tyrosine 905, in the activation loop, whose phosphorylation stabilizes the active conformation of the catalytic domain , tyrosine 1015, a docking site for phospholipase Cg (Borrello et al., 1996) and tyrosine 1062. This last residue is embedded in an NKLpY (single-letter aminoacid code) motif and mediates recruitment of various proteins to RET and RET/PTC (Hayashi et al., 2000; Manie' et al., 2001) . Shc and FRS2 are recruited to pY1062 via their phosphotyrosine binding (PTB) domains (Melillo et al., 2001; Mercalli et al., 2001) and, by bridging RET/PTC to Grb2-Sos complexes, they play a key role in the activation of Ras small GTPases .
By using oligonucleotide microarrays, we have found that osteopontin (OPN) is one of the most heavily RET/ PTC3-induced transcripts in PC Cl 3 thyroid follicular cells (Melillo RM, Castellone MD, Kruhoffer M, Orntoft TF Santoro M, unpublished) . OPN, also known as secreted phosphoprotein 1(spp1), is a highly acidic calcium-binding glycosylated phosphoprotein. OPN is also regarded as a cytokine (ETA-1, Early T-lymphocyte antigen or IL-28) regulating T helper cell-1 function (Ashkar et al., 2000; Chabas et al., 2001) . CD44 is one of the cell surface receptors for OPN (Weber et al., 1996) . Furthermore, OPN contains an RGD (single-letter amino-acid code) peptide that binds av-containing integrins (Miyauchi et al., 1991) . By binding to these receptors, OPN supports various functions including chemotaxis, cell attachment and cell migration. Recently, much interest has focused on the association of OPN with tumorigenesis and metastasis formation. OPN is expressed in many neoplastic tissues, such as colon, breast, prostate and lung carcinomas, being a circulating plasma marker for several neoplasms (for a review, see Weber, 2001) .
Here, we show that signals elicited at the level of specific RET/PTC tyrosine residues stimulate an OPN-CD44 autocrine loop sustaining proliferation and invasiveness of transformed thyrocytes.
Results

RET/PTC induces OPN upregulation in PC Cl 3 cells
We used the oligonucleotide GeneChip s Rat Genome U34 Set (Affymetrix, SantaClara, CA, USA) to detect genes that are induced in thyroid cells upon RET/PTCmediated transformation. Comparative analysis was performed by the GeneChip s software: 87 genes were upregulated ofivefold in RET/PTC3-transformed cells with respect to parental cells. One of the most strongly upregulated genes was OPN (9.4-folds) (Melillo RM, Castellone MD, Kruhoffer M, Orntoft TF Santoro M, unpublished) .
We sought to confirm microarray data by quantitative RT-PCR (Q-PCR); we also asked whether OPN overexpression was specifically linked to the RET/PTC3 variant or it was a feature of different RET/PTC oncogenes ( Figure 1a) . Quantitation of the OPN mRNA by Q-PCR showed o10-fold OPN induction in RET/ PTC1-and RET/PTC3-expressing thyrocytes ( Figure 1b) . Thus, microarray screen underestimated OPN upregulation. To ascertain whether OPN upregulation was linked to RET/PTC expression and was not a late secondary effect of cell transformation, we analysed OPN mRNA expression by semiquantitative RT-PCR in PC Cl 3 cells expressing a doxycyclineinducible RET/PTC3. Actin mRNA detection was used for normalization. RET/PTC3 mRNA started to be detected at 12 h of doxycycline treatment and accumulated thereafter (Figure 1c ). OPN transcripts were barely detectable in unstimulated cells. In stimulated cells, OPN upregulation followed that of RET/PTC3, starting after 24 h and peaking after 48 h of doxycycline treatment. Upon doxycycline washout, expression of both RET/PTC3 and OPN was no longer detectable ( Figure 1c ).
To confirm these findings, cells stably expressing RET/PTC1 or RET/PTC3 oncogenes were harvested, protein lysates were obtained and OPN protein levels were examined by Western blotting; housekeeping tubulin detection was applied to confirm equal gel loading. Accumulation of OPN protein was detected in RET/PTC1-and RET/PTC3-transformed cells (Figure 1d ).
OPN upregulation depends on tyrosines 1015 and 1062 of RET/PTC
OPN mRNA levels were measured by semiquantitative RT-PCR in mass populations of PC Cl 3 cells stably Immunocomplexes were revealed by enhanced chemiluminescence. As a control of the specificity of the antibody, anti-OPN was preincubated with a fivefold molar excess of recombinant OPN. Anti-p-tubulin antibodies were used for normalization expressing RET/PTC3, a kinase-dead mutant (K758M) or mutants harbouring substitutions of tyrosines 1015 or 1062 to phenylalanine (Figure 2a ). Figure 2b shows that OPN stimulation was strongly dependent on the catalytic activity of RET/PTC3 and the integrity of tyrosine 1062. It was also dependent on tyrosine 1015, although the mutation of this last residue impaired OPN stimulation at a lower extent than mutation of Y1062 (Figure 2b) . Accordingly, when RET/PTC3 kinase was turned-off by a 48 h treatment with an RET/PTC3 kinase inhibitor (ZD6474, 1 mM) (Carlomagno et al., 2002) , OPN mRNA was strongly downregulated (Figure 2b ). One possible mediator of OPN upregulation was the Ras small GTPase. Indeed, oncogenic Ras stimulates OPN expression in various cell types (Guo et al., 1995) , and Y1062 is a crucial residue mediating Ras stimulation in PC Cl 3-RET/PTC cells . RNA was extracted from PC Cl 3 cells transformed by constitutively active v-Ha-Ras and used to assess OPN mRNA levels in comparison to parental cells. Similar to RET/PTC-expressing cells, PC-Ha-Ras cells featured high levels of OPN transcripts ( Figure 2c) .
Quantitation of the OPN mRNA by Q-PCR showed othreefold inhibition of OPN induction upon mutation of Y1015; mutation of Y1062 virtually abrogated OPN upregulation (Figure 2d ). Furthermore, a 24 h treatment of RET/PTC3-expressing thyrocytes with 35 mM PD98059 (a selective MEK1 inhibitor) sharply reduced OPN upregulation (Figure 2d ). Thus, OPN upregulation by RET/PTC likely depends on the cooperation between Ras/MAPK stimulation by Y1062 and signals derived from Y1015.
PC-RET/PTC cells feature CD44 upregulation
OPN exerts biological effects by binding two types of cell surface receptors: CD44 and av-containing integrins. We analysed PC-RET/PTC cells for CD44 and av integrins expression by semiquantitative RT-PCR. The expression of av integrins was detected at similar levels in normal and transformed cells (data not shown). Notably, CD44 resulted among the RET/PTC upregulated genes (fivefolds) in our microarray screening (Melillo RM, Castellone MD, Kruhoffer M, Orntoft TF Santoro M, unpublished) . By amplifying exons 1-2 of CD44 mRNA, we found that CD44 mRNA was upregulated in PC Cl 3 cells transformed by RET/PTC1 or RET/PTC3 in comparison to parental cells, this upregulation being impaired, similarly to OPN, by a 24 h treatment with 35 mM PD98059 (Figure 3a) . Quantitation of RET/PTC-mediated CD44 mRNA stimulation was obtained by real-time PCR (Figure 3b ). Finally, immunoblot experiments confirmed CD44 upregulation, showing a strong upregulation of a broad band of relative molecular mass of about 90 kDa likely containing multiple CD44 protein species (Figure 3c ). Accumulation of CD44 protein in RET/PTC-expressing cells was even stronger than accumulation of CD44 mRNA, suggesting the contribution of post-transcriptional events. CD44 transcripts are subject to alternative splicing. CD44 pre-mRNA is encoded by 20 exons. The constant 5 0 -terminal five exons encode the N-terminal extracellular portion of the CD44 protein, while the constant 3 0 -terminal five exons encode the transmembrane and the short cytosolic tail. Additional 10 exons (variant 'v1-v10' exons) are alternatively spliced and code for the extracellular membrane-proximal stem structure. Cancer cells often overexpress CD44 variants that include variable numbers of small 'v' exons. The presence of the v6 exon has been reported to be important for efficient OPN binding, while v3 is important for the binding of heparin-associated growth factors (Ponta et al., 2003) . Thus, by using different combinations of amplimers, we explored whether CD44 transcripts, accumulated in RET/PTC-transformed thyroid cells, contained variant exons. Figure 3d shows that CD44 mRNAs upregulated in PC-RET/PTC cells contained v3, v6 or both v3 and v6 exons. Overexpression of CD44 mRNAs was strongly dependent on Y1062, but not on Y1015. CD44 expression was induced by v-Ha-Ras, as well ( Figure 3d ).
OPN cooperates with RET/PTC to increase DNA synthesis of PC Cl 3 cells
We asked whether OPN upregulation played any role in the establishment of the neoplastic phenotype of RET/ PTC-transformed PC Cl 3 cells. We either stimulated cells with recombinant purified OPN or transduced cells with a lentiviral vector for OPN fused to enhanced GFP autofluorescent protein (OPN-GFP: OG) (Medico et al., 2001) (Figure 4a ). For lentiviral transduction, normal and RET/PTC3-transformed PC Cl 3 cells were subjected to three subsequent rounds of infection with high titre OG vector (multiplicity of infection o1). OG transduction was confirmed by flow cytometry: 49.21% of PC Cl 3 and 48.53% of PC-RET/PTC3 cells scored GFP-positive (not shown). Western blot with an anti-OPN antibody confirmed OG transduction: of note, OG migrated more slowly than endogenous OPN protein due to the GFP protein moiety (Figure 4a) .
We asked whether OPN stimulated proliferation of RET/PTC-expressing cells. As a measure of DNA synthesis, we counted BrdU-positive cells upon a 1 h BrdU pulse. Average results of three independent experiments are reported in Figure 4b . OG gene transduction potently stimulated the rate of BrdU incorporation in RET/PTC3-transfomed cells (about 10-fold increase). Treatment with recombinant OPN also stimulated DNA synthesis of transformed thyroid cells, albeit at a lower extent (about fivefold increase). Notably, in both cases, the response of parental cells to OPN was significantly smaller than that of RET/PTC3-transfomed cells (Figure 4b ). This could be due to the parallel upregulation of the CD44 receptor in transformed cells or to OPN cooperation with additional pathways triggered by RET/PTC. Treatment with anti-OPN-blocking antibodies (5 mg/ml), but not with nonspecific IgG, impaired DNA synthesis of both PC-RET/ PTC3 and OPN-stimulated PC-RET/PTC3 cells (Figure 4b) . Thus, although in many cell systems OPN has been shown to produce effects other than cell mitogenesis (Zhang et al., 2003) , in RET/PTC-transformed thyrocytes (see also below) OPN exerts detectable stimulation of DNA synthesis.
OPN cooperates with RET/PTC to increase invasiveness of PC Cl 3 cells
We examined cell invasiveness through Matrigel in basal conditions, upon OG transduction and towards exogenous recombinant OPN in the lower chamber of transwells. Figure 5a shows that PC-RET/PTC3 cells had basal levels of invasiveness higher than parental cells. Treatment with exogenous OPN further induced migratory response of PC-RET/PTC3 cells but not of parental cells (Figure 5a ). Importantly, PC-RET/PTC3 migration through Matrigel was inhibited by pretreatment with anti-OPN-blocking antibodies, but not by nonspecific IgG (Figure 5a ). Also, anti-CD44-blocking antibodies (IM7) blocked cell migration, consistent with known effects exerted by CD44 either upon binding to OPN (Lin et al., 2000; Weiss et al., 2001) or when triggered otherwise. Finally, OG gene transduction strongly stimulated Matrigel invasion of RET/PTC3-transformed cells (Figure 5b ), while it only slightly stimulated that of parental cells (not shown). These effects were inhibited by anti-CD44 antibodies, as well (Figure 5b) .
Finally, we asked whether OPN increased the capacity of PC Cl 3 cells to spread in tridimensional type I collagen gels. When seeded in collagen, wild-type PC Cl 3 cells showed a round phenotype and no spreading ability ( Figure 6 ). In contrast, a sizeable fraction of PC-RET/PTC3 cells dispersed in the collagen matrix during the first few hours of incubation ( Figure 6 ). OG gene transduction significantly increased spreading ability of RET/PTC3 cells. According to known effects of CD44 in mediating cell spreading, these effects were reduced when cells were incubated with anti-CD44 antibodies ( Figure 6 ). After 48 h, most RET/PTC cells lost the spreading phenotype and started to die, while OG-expressing cells continued to be alive and spreading (not shown).
OPN and CD44 overexpression in human thyroid papillary carcinoma cell lines
To confirm our findings in a different cell system, we used human thyroid carcinoma cells. TPC1 (Ishizaka et al., 1990) and FB2 (Basolo et al., 2002) are human cell lines established from thyroid papillary carcinomas spontaneously harbouring the RET/PTC1 oncogene. Both cancer cell lines expressed increased levels of OPN (Figure 7a ) and CD44 (Figure 7b ) with respect to P5, a primary culture of normal human thyrocytes. We transduced TPC1 cells with the OG lentiviral vector: 70.62% of cells scored GFP-positive (not shown). OG gene transduction significantly stimulated the rate of BrdU incorporation in TPC1 cells (about fivefold increase). Treatment with recombinant OPN also stimulated DNA synthesis of TPC1 cells (about 2.5-fold increase). Treatment with anti-OPN-blocking antibodies (5 mg/ml), but not with nonspecific IgG (not shown), impaired DNA synthesis of TPC1 and OPNtreated TPC1 cells (Figure 7c ).
We examined cell invasiveness through Matrigel in basal conditions and towards exogenous recombinant OPN. Figure 7d shows that treatment with exogenous OPN induced a strong migratory response of TPC1 cells. Migration through Matrigel was inhibited by Where indicated, blocking anti-CD44 or -OPN antibodies were used. In this case, cells were pretreated for 15 min with the required antibody (10 mg/ml) and then seeded in transwells in which the lower chamber contained the antibody (20 mg/ml). Cells were seeded in the upper chamber and incubated for 24 h. Thereafter, filters were fixed and stained. The upper surface was wiped clean and cells on the lower surface were photographed. This figure is representative of three independent experiments pretreatment with anti-OPN-blocking antibodies, but not by nonspecific IgG (Figure 7d ).
When seeded in tridimensional type I collagen gel, TPC1 cells showed a flat elongated phenotype and modest spreading ability (Figure 7e ). OG gene transduction significantly increased proliferative and spreading ability of TPC1 cells, these effects being greatly reduced when cells were incubated with anti-CD44 antibodies (Figure 7e ).
Materials and methods
Plasmids, recombinant proteins, antibodies and cell lines
All the constructs used in this study encode the short (RET-9) RET spliced form and were cloned in pCDNA3(Myc-His) (Invitrogen, Groningen, The Netherlands). For simplicity, we number the residues of RET/PTC proteins according to the corresponding residues in unrearranged RET. RET/PTC1 and RET/PTC3 constructs are described elsewhere (Melillo et al., 2001) . RET/PTC3(KÀ) is a kinase-dead mutant, carrying the substitution of the catalytic lysine (residue 758 in full-length RET) with a methionine. RET/PTC3(Y1062F) and RET/ PTC3(Y1015F) carry substitutions of the indicated tyrosines with phenylalanine residues .
Parental and transformed PC Cl 3 cells were cultured in Coon's modified Ham F12 medium supplemented with 5% calf serum and a mixture of thyrotropin (10 mU/ml), hydrocortisone (10 nM), insulin (10 mg/ml), apo-transferrin (5 mg/ml), somatostatin (10 ng/ml) and glycyl-histidyl-lysine (10 ng/ml) (Sigma Chemical Co., St Louis, MO, USA) according to Fusco et al. (1987) . PC Cl 3 transfected with RET/PTC1, RET/PTC3, Y1015F, Y1062F and K758M mutants have been described previously . PC Cl 3 transformed by v-Ha-Ras have been described (Fusco et al., 1987) . A PC Cl 3 cell line expressing RET/PTC3 in a doxycyline-dependent manner was obtained by sequential stable transfection with expression vectors for the tetracycline(tet)-dependent transactivating rtTA protein and for tet-inducible RET/PTC3 (Saavedra et al., 2000) . To induce RET/PTC3 expression, cells were treated for different times with 1 mg/ml doxycycline. TPC1 (Ishizaka et al., 1990 ) and FB2 (Basolo et al., 2002) cell lines derive from RET/PTC1-positive human PTC and were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FCS (Sigma Chemical Co.). The P5 primary culture of normal human thyroid follicular cells was a kind gift of F Curcio and was grown as described (Curcio et al., 1994) . Recombinant mouse OPN protein and blocking goat antimouse OPN antibody (AF808) were from R&D Systems (Minneapolis, MN, USA). Blocking monoclonal antibody against CD44 (IM7 clone) was from BD Biosciences (San Jose, CA, USA). Anti-OPN goat polyclonal antibody (K-20) and rabbit polyclonal anti-CD44 (H-300) were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Monoclonal anti ptubulin was from Sigma Chemical Co. Secondary antibodies were from Santa Cruz Biotechnology.
RNA extraction, PCR, real-time PCR
Total RNA was isolated by the RNeasy Kit (Qiagen, Crawley, West Sussex, UK) and subjected to on-column DNase digestion with the RNase-free DNase set (Qiagen) following the manufacturer's instructions. The quality of RNA was verified by electrophoresis through 1% agarose gel and visualization with ethidium bromide. Random-primed firststrand cDNA was synthesized in a 50 ml reaction volume starting from 2 mg RNA by using the Gene Amp RNA PCR Core Kit (Applied Biosystems, Warrington, UK). PCR amplification was performed using the GeneAmp RNA PCR Core Kit system following the manufacturer's instructions. To exclude DNA contamination, each PCR reaction was also performed on untranscribed RNA. Levels of b-actin transcripts were used as a control for equal RNA loading. RT-PCR products were loaded on 2% agarose gel, stained with ethidium bromide and the image saved by the Typhoon 8600 laser scanning system (Amersham Pharmacia Biotech, Bucks, England). The density and width of each band was quantified using the IMAGEQUANT 5.0 software.
Quantitative PCR reactions were performed by using the SYBR Green PCR Master mix (Applied Biosystems) in the iCycler apparatus (Bio-Rad, Munich, Germany). Amplification reactions (25 ml final reaction volume) contained 200 nM of each primer, 3 mM MgCl 2 , 300 mM dNTPs, 1 Â SYBR-Green PCR buffer, 0.1 U/ml AmpliTaq Gold DNA Polymerase, 0.01 U/ml Amp Erase, RNase-free water and 2 ml cDNA samples. Thermal cycling conditions consisted of an initial cycle of 2 min at 501C, a cycle of 10 min at 951C and 40 cycles of 15 s of denaturation (951C) followed by 1 min of annealing/ extension (601C). To verify the absence of nonspecific products, 80 cycles of melting (551C for 10 s) were performed. In all cases, the melting curve confirmed that a single product was generated. Real-time amplification was monitored by measuring the increase in fluorescence caused by the SYBRGreen binding to double-stranded DNA. Fluorescent threshold values were measured in triplicate and fold changes were calculated by the formula: 2À
, where DCt is the difference between the amplification fluorescent thresholds of the mRNA of interest and the b actin mRNA.
Primers were designed by using a software available at http://www-genome.wi.mit.edu/cgi-bin/primer/primer3_www. cgi and synthesized by the MWG biotech (Ebersberg, Germany). Primers sequences were as follows: ratb actin forward: 5 0 -GTCAGGCAGCTCATAGCTCT-3 
Protein extraction and Western blotting
Protein extractions and immunoblotting experiments were performed according to standard procedures. Briefly, cells were harvested in lysis buffer (50 mM HEPES, pH7,5, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1 mM EGTA, 1.5 mM MgCl 2 , 10 mM NaF, 10 mM sodium pyrophosphate, 1 mM Na 3 VO 4 , 10 mg of aprotinin/ml, 10 mg of leupeptin/ml) and clarified by centrifugation at 10 000 g. Protein concentration was estimated with a modified Bradford assay (Bio-Rad).
Immune complexes were detected with the enhanced chemiluminescence kit (ECL, Amersham). Signal intensity was analysed at the Phosphorimager (Typhoon 8600, Amersham Pharmacia Biotech) interfaced with the ImageQuant software.
Lentiviral infection with the OPN-GFP fusion gene
The lentiviral transfer vector pLC-OG, standing for Lentiviral (vector)-CMV (promoter)-OPN-GFP (transgene), is described elsewhere (Medico et al., 2001) . The virus was produced by transient transfection of 293T cells with pLC-OG together with the VSV-G and pCMVR8.93 plasmids, as described. Viral p24 concentration was determined by HIV-1 p24 Core profile ELISA (NEN Life Science Products). Transduction experiments were performed by adding a 1 : 2 dilution of the viruscontaining 293T supernatant onto cells in six-well plates (Costar) in the presence of polybrene (8 mg/ml). Transduced cells were checked by flow cytometry and Western blot for expression of the recombinant protein.
BrdU incorporation
DNA synthesis was measured by the 5 0 -bromo-3 0 -deoxyuridine Labeling and Detection Kit from Boehringer Mannheim (Germany). Cells were seeded on glass coverslips, BrdU was added to the cell culture media at a final concentration of 100 mg/ml. Cells were incubated for 1 h, permeabilized with Triton X-100 (0.2%) and fixed with paraformaldehyde (4%) prior to staining. Coverslips were incubated with anti-BrdU mouse monoclonal antibody and with an FITC-conjugated anti-mouse antibody. All coverslips were counterstained in PBS containing Hoechst 33258 (final concentration, 1 m/ml; Sigma Chemical Co.), rinsed in water and mounted in Moviol on glass slides. The fluorescent signal was visualized with an epifluorescent microscope (Axiovert 2, Zeiss) (equipped with a Â 100 lens) interfaced with the image analyzer software KS300 (Zeiss).
Matrigel invasion
In vitro invasiveness through Matrigel was assayed using Transwell cell culture chambers according to described procedures (Yue et al., 1994) . Briefly, confluent cell mono-layers were harvested with trypsin/EDTA and centrifuged at 800 g for 10 min. The cell suspension (1 Â 10 5 cells/well) was added to the upper chamber of a prehydrated polycarbonate membrane filter of 8 mM pore size (Costar, Cambridge, MA, USA) coated with 35 mg Matrigel (Collaborative Research Inc., Bedford, MA, USA). The lower chamber was filled with F12 complete medium and, when required, purified intact OPN. When required, the cells were pretreated with blocking antibodies for 20 min. Plates were incubated at 371C in a humidified incubator in 5% CO 2 and 95% air for 24 h. Nonmigrating cells on the upper side of the filter and Matrigel were wipped off and migrating cells on the reverse side of the filter were stained with 0.1% crystal violet in 20% methanol for 15 min, counted and photographed.
Cell spreading in collagen gel
Cells were harvested from cultures using trypsin-EDTA and resuspended in gelling solution prepared as described (Medico et al., 1996) . Briefly, eight parts of type I collagen solution (2 mg/ml) (ICN Biomedicals, Eschwege, Germany) was mixed with one part of 10 Â DMEM and one part of HEPES 0.5 M (pH 7.4) and kept on ice to prevent premature gelation. Resuspended cells were seeded into 24-well plates (4 Â 10 4 / well). After gelation, F12 medium containing 5% FCS and six hormones was added. Cell spreading was examined at regular time intervals for 4 days.
Discussion
RET/PTC rearrangements are prevalent in thyroid papillary carcinomas and experimental evidence indicate that they are able to initiate thyroid carcinogenesis. This not withstanding, very little is known about the mechanisms by which RET/PTC oncogenes transform thyroid follicular cells. Model systems of thyroid follicular cells have been widely used to study growth regulation and neoplastic transformation (Kimura et al., 2001) . By using PC Cl 3 cells, here we identify OPN as a major transcriptional target of RET/PTC in thyroid cells. By using recombinant OPN protein, an OPN-expressing lentivirus and OPN-blocking antibodies, we show that OPN upregulation is implicated in mitogenic and motile phenotype of RET/ PTC-transformed PC Cl 3 cells. These results were confirmed in human cell lines spontaneously harbouring the RET/PTC1 oncogene.
OPN binds cell surface av-containing integrins and the hyaluronate receptor CD44. CD44, in turn, has been implicated in cell-cell and cell-matrix interactions and homing of tumour cell metastasis (Ponta et al., 2003) . CD44 is a signalling receptor able to induce activation of the phosphatidylinositol 3-kinase/Akt pathway (Kamikura et al., 2000; Lin and Yang-Yen, 2001 ) and to associate to ezrin to control cell motility in a PKC-regulated manner (Legg et al., 2002) . We show that CD44 is upregulated in RET/PTC-transformed cells. It is possible that, in thyroid cells, OPN effects are mediated in part by av-containing integrins and that CD44 upregulation affects the transformed phenotype per se independently of OPN (for instance by lateral recruitiment of other membrane proteins). However, some evidences suggest that CD44 is implicated in OPN signalling in RET/ PTC-transformed PC Cl 3 cells. Indeed, the increased response to OPN of RET/PTC-transformed with respect to parental cells parallels CD44 overexpression. Furthermore, anti-CD44 antibodies (Lin et al., 2000; Weiss et al., 2001) reduced OPN effects in thyroid cells. Finally, PC-RET/PTC cells overexpress CD44 mRNAs containing the v6 exon, important for efficient OPN binding. Intriguingly, CD44 and its splicing variants are often found overexpressed in human thyroid tumors (Ermak et al., 1995; Bartolazzi et al., 2001) . Whether RET/PTC solely induces CD44 overexpression or it also stimulates CD44 activity (for instance by the recently described PKC-mediated phosphorylation mechanism, Legg et al., 2002) remains to be determined.
An intact kinase activity and phosphorylation of Y1062 are essential for efficient stimulation of OPN and CD44 by RET/ PTC. OPN upregulation, in turn, depended also on Y1015. Of note, both Y1062 and Y1015 are required for RET/PTCmediated cell transformation Borrello et al., 1996) and they are constitutively phosphorylated in RET/PTC proteins in human thyroid cancer specimens (Salvatore et al., 2000) . Moreover, both tyrosines are required for thyroid tumors formation in RET/PTC1-transgenic mice (Buckwalter et al., 2002) . Tyrosine 1015 is the docking site for PLCg, implicated in RET-mediated activation of protein kinase Ca (PKCa) (Andreozzi et al., 2003) . Tyrosine 1062 is implicated in the activation of multiple signalling pathways (Hayashi et al., 2000) , including the Ras one (Melillo et al., 2001) . The OPN promoter contains multiple AP-1 and ETS-family proteins binding sites (Chang and Prince, 1993; Guo et al., 1995) . Indeed, it responds to PKCa triggering (Chang and Prince, 1993) and to oncogenic Ras, as well (Guo et al., 1995 and this paper) . We suggest that in PC Cl 3 cells, CD44 upregulation is determined by signals starting from Y1062 and leading to Ras/ MAPK activation, while OPN upregulation is the result of the cooperation of multiple signalling pathways downstream RET/PTC, the Ras/MAPK pathway being one of them.
In conclusion, our data demonstrate that RET/PTC signalling triggers the formation of an autocrine loop involving OPN and CD44 that stimulates proliferation and motility of PC Cl 3 cells. These findings prompt further studies to ascertain whether OPN could be a useful PTC tumour marker and a promising therapeutic target.
